{
    "clinical_study": {
        "@rank": "136011", 
        "acronym": "TRYPHON", 
        "arm_group": {
            "arm_group_label": "Preoperative aTARE", 
            "arm_group_type": "Experimental", 
            "description": "The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety of transarterial radioembolization prior\n      to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma"
        }, 
        "brief_title": "Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Liver Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to assess the peri-operative morbidity and mortality of\n      supraselective ablative transarterial radioembolization prior to surgical resection or\n      radiofrequency in cirrhotic patients with HCC"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years.\n\n          -  Cirrhotic liver demonstrated by typical liver dysmorphy on imaging and/or liver\n             biopsy.\n\n          -  HCC  with at least one lesion measuring more than 1 cm in diameter with a single\n             dynamic imaging technique (CT or MRI), showing intense arterial uptake followed by\n             washout of contrast in the venous-delayed phases, or diagnosed by biopsy.\n\n          -  Borderline resectable disease eligible for surgical resection or radiofrequency\n             destruction.\n\n          -  No extra-hepatic dissemination.\n\n          -  ECOG Performance status < 2.\n\n          -  Women of child-bearing potential must agree to use adequate contraception (hormonal\n             or barrier method of birth control, abstinence) prior to study entry and for the\n             duration of study participation. Should a woman become pregnant or suspect she is\n             pregnant while participating in this study, she should inform her treating physician\n             immediately.\n\n          -  Signed written informed consent (approved by an Independent Ethics Committee)\n             obtained prior to any study specific baseline procedures.\n\n        Exclusion Criteria:\n\n          -  Decompensated cirrhosis (Child Pugh B, C).\n\n          -  Extra-hepatic tumour spread.\n\n          -  Previous or concomitant malignancies within five years other than basal cell\n             carcinoma of the skin.\n\n          -  Pregnancy, lactation or refusal to use adequate contraceptive measures (hormonal or\n             barrier method of birth control, abstinence).\n\n          -  Pre-existing other hepatic disease (liver abscess, hepatic sarcoidosis or\n             tuberculosis, sclerosing cholangitis, \u2026).\n\n          -  Previous trans-arterial radioembolization (TARE).\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition of the administered materials.\n\n          -  Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular\n             incident within the last six months.\n\n          -  Major surgery within four weeks.\n\n          -  Uncontrolled concurrent illness including, but not limited to ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Uncontrolled Diabetes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686880", 
            "org_study_id": "TRYPHON"
        }, 
        "intervention": {
            "arm_group_label": "Preoperative aTARE", 
            "description": "Patients will receive Sirsphere trans-arterial radioembolization before surgery", 
            "intervention_name": "Sirsphere trans-arterial radioembolization", 
            "intervention_type": "Device", 
            "other_name": [
                "TARE", 
                "SIRT"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatocellular Carcinoma", 
            "Liver Cirrhosis", 
            "radioembolization", 
            "SIRT", 
            "TARE", 
            "Sirspheres", 
            "neoadjuvant", 
            "liver cancer"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "link": [
            {
                "description": "Jules Bordet Institute", 
                "url": "http://www.bordet.be/"
            }, 
            {
                "description": "Erasme Hospital", 
                "url": "http://www.erasme.ulb.ac.be/"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "investigator": [
                    {
                        "last_name": "Alain Hendlisz, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Am\u00e9lie Deleporte, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Patrick Flamen, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Philippe Delatte, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hazem El Mansy, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "Erasme Hosptial"
                }, 
                "investigator": [
                    {
                        "last_name": "Vincent Donckier, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Valerio Lucidi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean-Luc Van Laethem, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maria Antonietta Bali, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Christophe Moreno, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Denis Brisbois, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Delphine Degre, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pieter Demetter, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver", 
        "overall_contact": {
            "email": "alain.hendlisz@bordet.be", 
            "last_name": "Alain Hendlisz, MD", 
            "phone": "+32 0 2 541 35 41"
        }, 
        "overall_contact_backup": {
            "email": "vincent.donckier@erasme.ulb.ac.be", 
            "last_name": "Vincent Donckier, MD, PhD", 
            "phone": "+32 2 541 72 92"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut Jules Bordet", 
                "last_name": "Alain Hendlisz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Erasme University Hospital", 
                "last_name": "Vincent Donckier, MD, PHD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "peri-operative morbidity of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC (starting from date of inclusion till 90 days after surgery or hospital discharge if more than 90 days)", 
            "measure": "Peri-operative morbidity", 
            "safety_issue": "Yes", 
            "time_frame": "3 months after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686880"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of the overall disease free survival and Overall Survival", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Estimation of disease free survival and overall survival rates after 1 and 3 years", 
                "measure": "One and three years survival", 
                "safety_issue": "No", 
                "time_frame": "one and three years"
            }, 
            {
                "description": "Assessment of tumour size regression after Trans-arterial radioembolization by MRI", 
                "measure": "Tumor regression", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after Trans-arterial radioembolization"
            }, 
            {
                "description": "Assessment of imaging parameters changes (DW-MRI, FDG-PET/CT) and MAA-SPECT-CT in relation to the outcome measured by tumour regression after TARE, disease free and overall survival.", 
                "measure": "Functional Imaging", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Assessment of TARE induced liver contralateral lobe hypertrophy (volumetric measurement by MRI).", 
                "measure": "Contra-lateral Lobe Hypertrophy", 
                "safety_issue": "No", 
                "time_frame": "3 Years"
            }
        ], 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}